231.84
price up icon1.75%   3.98
pre-market  Pre-market:  231.91   0.07   +0.03%
loading
Quest Diagnostics Inc stock is traded at $231.84, with a volume of 1.14M. It is up +1.75% in the last 24 hours and up +10.46% over the past month. Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$227.86
Open:
$225.95
24h Volume:
1.14M
Relative Volume:
1.22
Market Cap:
$25.59B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
25.57
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
+11.64%
1M Performance:
+10.46%
6M Performance:
+25.84%
1Y Performance:
+37.55%
1-Day Range:
Value
$224.97
$231.95
1-Week Range:
Value
$204.10
$237.78
52-Week Range:
Value
$165.78
$237.78

Quest Diagnostics Inc Stock (DGX) Company Profile

Name
Name
Quest Diagnostics Inc
Name
Phone
(973) 520-2700
Name
Address
500 PLAZA DRIVE, SECAUCUS
Name
Employee
57,000
Name
Twitter
@QuestDX
Name
Next Earnings Date
2026-07-23
Name
Latest SEC Filings
Name
DGX's Discussions on Twitter

Compare DGX vs TMO, DHR, IDXX, A, NTRA

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
DGX icon
DGX
Quest Diagnostics Inc
231.84 25.59B 11.28B 1.07B 1.33B 9.0657
TMO icon
TMO
Thermo Fisher Scientific Inc
559.53 207.93B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
196.50 138.14B 24.78B 3.68B 5.29B 5.1743
IDXX icon
IDXX
Idexx Laboratories Inc
556.20 43.87B 4.45B 1.10B 1.06B 13.59
A icon
A
Agilent Technologies Inc
137.89 38.94B 7.23B 1.41B 1.09B 4.979
NTRA icon
NTRA
Natera Inc
258.03 36.95B 2.50B -226.32M 71.51M -1.6412

Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-30-26 Upgrade Barclays Equal Weight → Overweight
Aug-25-25 Downgrade Robert W. Baird Outperform → Neutral
Apr-02-25 Initiated Redburn Atlantic Buy
Mar-04-25 Downgrade Citigroup Buy → Neutral
Jan-06-25 Upgrade Leerink Partners Market Perform → Outperform
Dec-17-24 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-10-24 Resumed Jefferies Buy
Oct-23-24 Upgrade Robert W. Baird Neutral → Outperform
Aug-28-24 Resumed Evercore ISI In-line
Jul-10-24 Upgrade Citigroup Neutral → Buy
Feb-26-24 Initiated Leerink Partners Market Perform
Feb-07-24 Upgrade Jefferies Hold → Buy
Jan-03-24 Initiated Barclays Equal Weight
Dec-12-23 Upgrade BofA Securities Neutral → Buy
Jun-29-23 Initiated Piper Sandler Neutral
May-02-23 Downgrade BofA Securities Buy → Neutral
Apr-03-23 Upgrade Citigroup Sell → Neutral
Jan-23-23 Initiated Evercore ISI In-line
Nov-17-22 Downgrade Citigroup Neutral → Sell
Aug-22-22 Resumed Morgan Stanley Equal-Weight
Apr-04-22 Downgrade Citigroup Buy → Neutral
Feb-23-22 Downgrade UBS Buy → Neutral
Feb-02-22 Downgrade Jefferies Buy → Hold
Jan-28-22 Downgrade Deutsche Bank Buy → Hold
May-04-21 Upgrade UBS Neutral → Buy
Mar-12-21 Downgrade Robert W. Baird Outperform → Neutral
Oct-21-20 Upgrade Argus Hold → Buy
Jul-29-20 Upgrade KeyBanc Capital Markets Sector Weight → Overweight
Jul-14-20 Upgrade BofA Securities Neutral → Buy
Jun-09-20 Upgrade Wells Fargo Underweight → Equal Weight
Jun-02-20 Upgrade Deutsche Bank Hold → Buy
Apr-28-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-27-20 Upgrade Citigroup Neutral → Buy
Apr-27-20 Upgrade Wolfe Research Underperform → Peer Perform
Mar-27-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-08-20 Initiated Wells Fargo Underweight
Jan-07-20 Downgrade Barclays Overweight → Equal Weight
Dec-19-19 Upgrade BofA/Merrill Underperform → Neutral
Jul-15-19 Downgrade Goldman Neutral → Sell
Apr-02-19 Upgrade Jefferies Hold → Buy
Mar-18-19 Resumed Credit Suisse Neutral
Jan-31-19 Downgrade Argus Buy → Hold
Jan-17-19 Initiated UBS Neutral
Jan-03-19 Downgrade BofA/Merrill Neutral → Underperform
Dec-03-18 Downgrade BofA/Merrill Buy → Neutral
Nov-30-18 Downgrade Goldman Buy → Neutral
View All

Quest Diagnostics Inc Stock (DGX) Latest News

pulisher
01:21 AM

Form 4 Quest Diagnostics orporated For: 28 July By Investing.com - Investing.com South Africa

01:21 AM
pulisher
Jul 27, 2026

Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance

Jul 27, 2026
pulisher
Jul 27, 2026

Quest Diagnostics (NYSE: DGX) SVP adds shares via dividend reinvestment plan - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

Quest Diagnostics (NYSE: DGX) SVP acquires 34.0000 shares via dividend reinvestment - Stock Titan

Jul 27, 2026
pulisher
Jul 26, 2026

Quest Diagnostics (DGX) Leads S&P 500 Healthcare Gainers with 8. - GuruFocus

Jul 26, 2026
pulisher
Jul 26, 2026

Quest Diagnostics Incorporated (DGX) Stock forecasts - Yahoo Finance Singapore

Jul 26, 2026
pulisher
Jul 26, 2026

Quest Diagnostics stock trades steady as earnings and diagnostics demand shape investor focus - Ad-hoc-news.de

Jul 26, 2026
pulisher
Jul 25, 2026

Quest Diagnostics Inc (DGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Quest Diagnostics Inc (DGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail

Jul 25, 2026
pulisher
Jul 25, 2026

Quest Diagnostics Inc (DGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Quest Diagnostics Is Maintained at Outperform by Mizuho - Moomoo

Jul 25, 2026
pulisher
Jul 25, 2026

Quest Diagnostics Inc (DGX) Cash Flow - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

DGX|Quest Diagnostics Inc|Price:227.860|Chg%:-0.050 - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Quest Diagnostics Inc (DGX) Institutional Confidence - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Quest Diagnostics Inc (DGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 25, 2026
pulisher
Jul 24, 2026

Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Q2 2026 Quest Diagnostics Inc Earnings Call Transcript - GuruFocus

Jul 24, 2026
pulisher
Jul 24, 2026

Quest Diagnostics Q2 2026 Earnings: Net Income, Revenues, and Financial Highlights from SEC 10-Q Filing - Minichart

Jul 24, 2026
pulisher
Jul 24, 2026

QUEST DIAGNOSTICS INC : TRUIST SECURITIES RAISES TARGET PRICE TO $250 FROM $225 - Bitget

Jul 24, 2026
pulisher
Jul 24, 2026

UBS Adjusts Price Target on Quest Diagnostics to $232 From $220, Maintains Neutral Rating - marketscreener.com

Jul 24, 2026
pulisher
Jul 24, 2026

Baird Adjusts Quest Diagnostics Price Target to $255 From $236, Maintains Neutral Rating - marketscreener.com

Jul 24, 2026
pulisher
Jul 24, 2026

Barclays Raises Quest Diagnostics Price Target to $250 From $230, Maintains Overweight Rating - marketscreener.com

Jul 24, 2026
pulisher
Jul 24, 2026

Mizuho Securities Adjusts Quest Diagnostics Price Target to $260 From $235, Maintains Outperform Rating - marketscreener.com

Jul 24, 2026
pulisher
Jul 24, 2026

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $241.73, Implies 6% Upside - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance

Jul 24, 2026
pulisher
Jul 24, 2026

Deutsche Bank Adjusts Quest Diagnostics Price Target to $232 From $205, Maintains Hold Rating - marketscreener.com

Jul 24, 2026
pulisher
Jul 24, 2026

Truist Raises Price Target on Quest Diagnostics to $250 From $225, Keeps Hold Rating - marketscreener.com

Jul 24, 2026
pulisher
Jul 24, 2026

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $240.93, Implies 6% Upside - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results (NYSE:DGX) - Seeking Alpha

Jul 24, 2026
pulisher
Jul 24, 2026

Morgan Stanley Adjusts PT on Quest Diagnostics to $260 From $226, Maintains Overweight Rating - marketscreener.com

Jul 24, 2026
pulisher
Jul 24, 2026

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $239.27, Implies 5% Upside - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Quest Diagnostics stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de

Jul 24, 2026
pulisher
Jul 24, 2026

Quest Diagnostics Inc (DGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Trending Industry Today: Quest Diagnostics Leads Gains In CRO Stocks - Moomoo

Jul 24, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Inc (DGX) Shares Surge 8.6% -- What GF Score o - GuruFocus

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary - Yahoo Finance

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Continues to Build on Its Hospital Lab Collaborations - Morningstar

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $229.6, Implies 9% Upside - TradingView

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: St - GuruFocus

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics 2026: Revenue $3.04B, EPS $2.84— 10-Q Summary - TradingView

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics (NYSE: DGX) lifts Q2 EPS to $2.84 on 10% revenue growth - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Q2 Earnings Call Highlights - TradingView

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Stock Gains As Oncology Moves Impress Wall Street - StocksToTrade

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics Stock Hits 52-Week HighHere's WhyQuest Diagnostics (NYSE:DGX) - Benzinga

Jul 23, 2026
pulisher
Jul 23, 2026

Evercore ISI Cuts Quest Diagnostics Price Target to $240 From $225 - marketscreener.com

Jul 23, 2026
pulisher
Jul 23, 2026

Quest Diagnostics raises annual forecast on testing demand - Reuters

Jul 23, 2026

Quest Diagnostics Inc Stock (DGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
MTD MTD
$1,336.29
price up icon 0.69%
$189.47
price down icon 2.38%
IQV IQV
$213.22
price up icon 2.48%
WAT WAT
$371.20
price down icon 0.93%
$258.03
price down icon 1.51%
Cap:     |  Volume (24h):